← Eichor
Study identifier: NCT07604467 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome

Condition: Tako Tsubo Cardiomyopathy · Microvascular Dysfunction · CD34+ Stem Cells  ·  Sponsor: University Medical Centre Ljubljana

PhaseN/A
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.

This description comes directly from the study's public registry record.

Talk to the study team

Mark Jovanović, MD  ·  +38640977307  ·  mark.jovanovic@kclj.si

Principal Investigator  ·  gregor.poglajen@kclj.si

Always discuss trial participation with your own doctor first.

Locations (1)

Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, SloveniaLjubljana, Ljubljana, SloveniaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07604467